Ventana Sublicensing IP from Gen-Probe for ERG Protein Measurement | GenomeWeb

NEW YORK (GenomeWeb News) – Ventana Medical Systems today announced it is co-exclusively sublicensing certain patents and patents applications from Gen-Probe for the worldwide in vitro diagnostic rights to measure ERG protein expression by immunohistochemistry in prostate tissue.

Ventana, a Roche company, said that the license complements its existing worldwide co-exclusive sublicense under certain patents and patent applications for in situ hybridization for measuring ETS gene rearrangements, such as ERG gene rearrangements in tissue.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.